Paolo Chetta

Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist

M. Pearson, N. Kraut, Rachel Kroe-Barrett, 2020, Molecular Cancer Therapeutics.

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo

Julian E. Fuchs, M. Koegl, Barbara Mair, 2022, Nature Communications.